European urology最新文献

{"title":"Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.06.003","authors":"Armando Stabile, Francesco Montorsi","doi":"10.1016/j.eururo.2025.09.4128","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4128","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"19 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study","authors":"Ding Ding, Lei Qian, Di Jin, Xiang Zhou, Chunhua Rui, Ruiyun Zhang, Zehua Lu, Haitao Zhao, Qian Xia, Weijun Wei, Gang Huang, Jun Xia, Dengfeng Cao, Da Han, Jianjun Liu, Haige Chen, Weihong Tan","doi":"10.1016/j.eururo.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.08.008","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"1 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Yuan Du, Dan Liu, and Zhihui Guan’s Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167–75","authors":"Cameron Englman, Busola Adebusoye, Sue Mallett, Francesco Giganti, Caroline M. Moore","doi":"10.1016/j.eururo.2025.09.005","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.005","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"29 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145083703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction","authors":"Antonio Franco, Francesco Ditonno, Celeste Manfredi, Eugenio Bologna, Leslie Claire Licari, Luca Orecchia, Enrico Finazzi Agró, Alessandro Antonelli, Salvador Arlandis, Riccardo Autorino, Tufan Tarcan, Jean Nicolas Cornu, Dean Elterman, Steven Kaplan, Riccardo Lombardo, Kevin McVary, Silvia Secco, Luca Cindolo, Cosimo De Nunzio","doi":"10.1016/j.eururo.2025.09.004","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.004","url":null,"abstract":"<h3>Background and objective</h3>Minimally invasive surgical treatments (MISTs) for benign prostatic obstruction have been developed with the aim of providing superior symptom relief in comparison to pharmacological treatment, while minimizing the impact on sexual function. The aim of our study was to assess key MIST outcomes and to propose a definition of procedural success.<h3>Methods</h3>A systematic literature search was conducted in February 2025 in the PubMed, Scopus, Web of Science, and Cochrane Library databases. The protocol, which follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and PICOS (Population, Intervention, Comparator, Outcomes, Study design) criteria, was registered on PROSPERO as CRD42024543361. The review focused on randomized controlled trials and prospective studies evaluating surgical and functional outcomes of MISTs (Rezūm, UroLift, temporary implantable nitinol device [iTind], transperineal laser ablation [TPLA], Optilume) for BPO. We assessed the risk of bias and graded the certainty of evidence from the articles included. Pooled analyses were performed to compare perioperative and functional outcomes between study groups.<h3>Key findings and limitations</h3>The 24 studies included in the review found that most MISTs were effective, showing improvements at 12 mo of ≥50% in the International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax), and of ≥1 point for at quality of life (QoL) questionnaire. Anejaculation rates were 5% with TPLA, 3% with Rezūm, 1% with iTIND, and 0% with UroLift and Optilume. Complication and retreatment rates were low, although the follow-up duration was inconsistently reported and mainly limited to 24 mo. On the basis of these results, we propose a definition of procedural success that comprises achievement of all the following outcomes: IPSS reduction of ≥50%, Qmax improvement of ≥50%, QoL improvement of ≥50% (or ≥1 point), the absence of intraoperative complications and Clavien-Dindo grade ≥III postoperative complications, and preservation of erectile function and of antegrade ejaculation.<h3>Conclusions and clinical implications</h3>MISTs represent a promising tool for benign prostatic obstruction management and provide effective symptom relief while preserving sexual function.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"16 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145078520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer","authors":"Miguel Zugman, Ariê Carneiro, Fernando C. Maluf","doi":"10.1016/j.eururo.2025.09.008","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.008","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"68 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145078522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes","authors":"Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, Alberto Briganti, Francesco Montorsi","doi":"10.1016/j.eururo.2025.08.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.08.017","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"30 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145078521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy","authors":"Matthias Michael Heck, Jan Lehmann, Thomas Amiel, Herbert Rübben, Peter Albers, Johannes M. Wolff, Detlef Frohneberg, Patrick de Geeter, Axel Heidenreich, Tilman Kälble, Michael Stöckle, Thomas Schnöller, Arnulf Stenzl, Markus Müller, Michael Truss, Stephan Roth, Uwe-Bernd Liehr, Joachim Leißner, Thomas Bregenzer, Heidrun Rexer, Jürgen E. Gschwend","doi":"10.1016/j.eururo.2025.09.001","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.001","url":null,"abstract":"The extent of lymph node dissection (LND) at the time of radical cystectomy (RC) for bladder cancer (BC) may affect oncologic outcomes. We present updated long-term data from a prospective, multicenter, phase 3 trial involving patients with locally resectable, high-risk T1 grade 3 or muscle-invasive urothelial BC (T2–T4a M0) without neoadjuvant treatment (trial LEA AUO AB 25/02; NCT01215071). A total of 401 patients were randomly assigned 1:1 to either standard LND (sLND: obturator, internal, and external iliac nodes) or extended LND (eLND), which also included the deep obturator, common iliac, presacral, paracaval, interaortocaval, and para-aortic nodes up to the inferior mesenteric artery. Median follow-up for patients alive without disease recurrence was 58.4 mo. The primary endpoint was recurrence-free survival (RFS). Overall survival (OS) and cancer-specific survival (CSS) were secondary endpoints. eLND failed to show superiority over sLND for RFS (5-yr rate: 68% vs 60%; hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.56–1.14; <em>p</em> = 0.2) and OS (5-yr rate: 57% vs 51%; HR 0.84, 95% CI 0.64–1.12; <em>p</em> = 0.2). The CSS rate was significantly higher in the eLND arm (5-yr rate: 76% vs 65%; HR 0.65, 95% CI 0.43–0.96; <em>p</em> = 0.031), which is clinically meaningful. With long-term follow-up, this randomized controlled trial remains negative for the primary endpoint of RFS, but was positive for CSS. Therefore, meticulous LND using at least a standard template remains the recommended surgical approach for patients undergoing RC for BC.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"77 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145078523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non–clear-cell Renal Cell Carcinoma","authors":"Marine Potez, Seyed Behzad Jazayeri, Christopher Guske, Justin Miller, Johannes Ali, Michael Carter, Fatema Khambati, Jasreman Dhillon, Wade Sexton, Logan Zemp, Brandon Manley, Gabriel Roman Souza, Philippe E. Spiess, Matthew Beatty, Shari Pilon-Thomas, Jad Chahoud","doi":"10.1016/j.eururo.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.002","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"28 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind","authors":"Nazli Dizman, Hedyeh Ebrahimi, Alexander Chehrazi-Raffle","doi":"10.1016/j.eururo.2025.08.009","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.08.009","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"30 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Seminoma: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer","authors":"Axel Heidenreich, Anna Patrikidou, Torgrim Tandstad","doi":"10.1016/j.eururo.2025.08.013","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.08.013","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background</h2>Chemotherapy with three cycles of platinum, etoposide, and bleomycin (PEB) or four cycles of platinum and etoposide is the standard treatment option for clinical stage IIA/B seminoma, with relapse rates of 0–8% in clinical stage IIA and 8–14% in clinical stage IIB [1]. Historical use of radiation therapy with doses of 30 Gy for clinical stage IIA and 36 Gy for clinical stage IIB has resulted in relapse rates of 9–24% [1]. Despite low relapse rates and high cure rates, both treatment options are</section></section><section><section><h2>Critical issues for primary nerve-sparing RPLND</h2>RPLND in early metastatic seminoma represents an oncologically effective treatment if performed at high-volume centers by surgeons experienced in testicular cancer surgery. Therefore, primary nerve-sparing RPLND (nsRPLND) needs to be concentrated in tertiary referral centers, as recommended in the European Association of Urology (EAU) guidelines [1]. The EAU guidelines panel is currently evaluating primary RPLND as a treatment option in early-stage metastatic seminoma, and the next update will</section></section><section><section><h2>Conclusions</h2>In summary, nsRPLND for marker-negative clinical stage IIA/B seminoma is associated with a low rate of treatment-associated morbidity and a chemotherapy-free survival rate of 80–85% if performed in expert hands. Both the American Urological Association and National Comprehensive Cancer Network guidelines include primary nsRPLND in their evidence-based recommendations for the management of low-volume clinical stage IIA/B seminomas [11,12]. The EAU guidelines panel is currently evaluating primary</section></section>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"30 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}